Get a Deep Insight Into the Future of Targeted Therapeutics: Key Technologies, New Therapy Area Applications and Leading Players

Reportlinker.com announces that a new market research report related to the Pharmaceutical industry industry is available in its catalogue.

The Future of Targeted Therapeutics: Key technologies, new therapy area applications and leading players

In recent years, the maximization of blockbuster revenues has been compromised by generic price erosion and a decline in new drug approvals. Large pharmaceutical companies are coming under pressure to explore new R&D strategies and implement more cost-effective sourcing methods for innovative new molecules. The biotechnology industry is emerging as a hub of innovation for biomarker and new chemical entity (NCE) identification, and has become a vital component in the preclinical development of new drug technologies. As therapy focus shifts to treating the causal pathway of disease and not merely the symptomology, the majority of emerging targeted therapeutics are large molecule biologics, while monoclonal antibody therapies represents the fastest growing segment within the pharmaceutical industry. The Future of Targeted Therapeutics: Key technologies, new therapy area applications and leading players is a new report published by Business Insights that examines various types of targeted therapy within pharma pipelines, highlighting the molecules of greatest significance to major therapy areas. The key revenue drivers and product focus within targeted technology markets are also assessed. This report also measures the impact of the new model of targeted therapeutic development upon stakeholder demand and health economics. Discover the most promising targeted molecules within each therapeutic area, identify the pipeline potential of leading companies and align your R&D strategies with the latest innovations and development models...

Table of Contents

The Future of Targeted Therapeutics

Executive Summary 10

Emergence of targeted therapeutics 10

Analysis of stakeholder incentives 11

Types of targeted therapeutics 12

Role of targeted therapeutics in selected therapy areas 13

Chapter 1 Emergence of targeted

therapeutics 16

Summary 16

Introduction 17

Decline of the blockbuster model 18

The "nichebuster" model 22

The emergence of targeted therapeutics 23

Convergence of biotechnology and pharmaceutical companies 25

Licensing incentives 26

Risk management 29

Role of biomarkers and diagnostics 32

Academic research and technology transfer 34

Chapter 2 Analysis of stakeholder

incentives 36

Summary 36

Introduction 37

Institutional payors 37

Regulators 39

Patients and patient advocacy groups 41

Physicians 43

Pharmaceutical companies 44

Chapter 3 Types of targeted therapeutics 48

Summary 48

Introduction 49

Innovative small molecules 49

Mechanism of action 50

Examples 52

Gleevec 52

Lapatinib (Tykerd/Tyverb) 52

SNS-032 53

PLX4032 53

Market synopsis 53

Protein/Peptide drugs 54

Mechanism of action 55

Examples 57

AGRO100 57

PRX321 58

Market synopsis 58

Monoclonal antibodies and antibody-like structures 60

Mechanism of action 60

Examples 62

Rituximab (Rituxan) 62

Alemtuzumab (Campath) 62

Erbitux/cetuximab 63

Avastin/bevacizumab 64

Herceptin/trastuzumab 64

Ibritumomab tiuxetan (Zevalin) 65

Tositumomab (Bexxar) 65

Market synopsis 65

Nucleic acid therapies 67

Mechanism of action 68

Examples 68

Genasense (oblimersen sodium) 68

Nexagon 69

4-Thio FAC 69

Market synopsis 69

RNA interference 70

Mechanism of action 70

Examples 72

CALAA-01 72

siRNA AV-34 72

Bioral SiRNA 72

Market synopsis 72

Stem cell therapies 73

Market synopsis 74

Future therapeutic applications 74

Regulatory concerns 76

Gene therapy 76

Drug delivery and nanotechnology in targeted therapeutics 77

Mechanism of action 78

Examples 79

BioVant 79

ATI-1123 (docetaxel) 80

Rexin-G 80

Abraxane 80

131I-TM-601 81

Market synopsis 81

Conclusion 83

Chapter 4 Role of targeted therapeutics in selected therapy areas 86

Summary 86

The cancer market 87

Targeting cancer cells for destruction 88

Blocking growth signalling pathways 88

Epidemiology 88

Current treatments 90

Unmet needs and innovation 96

Medical Needs 96

High toxicity and side effect profiles 96

Variable efficacy rates 96

The multifactorial nature of disease 96

Targeting brain tumors 97

Economic Needs 97

Reimbursement policies 97

Targeted therapeutics in cancer 99

Antineoplastics 100

Innovative small molecule therapies 101

Monoclonal antibody therapies 102

Proteins and Peptides 103

Application of genetic technology 103

RNAi in cancer 104

Applications of nanotechnology 106

Novel drug delivery approaches 107

The Cardiovascular Market 108

Epidemiology 108

Current market scenario 109

Unmet needs and innovation 111

Pill burden and patient compliance 111

Inefficient mechanism of action 111

Drug delivery technology limitations 111

Targeted therapeutics in cardiovascular diseases 113

Protein and nucleic acid therapies 113

Targeted small molecule drugs 113

Monoclonal antibody therapies 114